[
    [
        {
            "time": "2022-10-15",
            "original_text": "FDA approves Novartis ScemblixÂ® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia",
            "features": {
                "keywords": [
                    "FDA",
                    "approves",
                    "Novartis",
                    "Scemblix",
                    "chronic myeloid leukemia"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-11-03",
            "original_text": "Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "Big Pharma",
                    "Q3 Results",
                    "FDA",
                    "Panel's Vote",
                    "PFE",
                    "COVID Jab"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-11-10",
            "original_text": "The Zacks Analyst Blog Highlights: Berkshire Hathaway, Visa, Novartis, Advanced Micro Devices and Deere",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst Blog",
                    "Berkshire Hathaway",
                    "Visa",
                    "Novartis",
                    "Advanced Micro Devices",
                    "Deere"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "financial services",
                    "technology",
                    "healthcare",
                    "agriculture"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        }
    ]
]